DOCSLIB.ORG

Effects of a Hydrochlorothiazide and Amiloride Combination on Plasma Magnesium in Patients with Essential Hypertension

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of a Hydrochlorothiazide and Amiloride Combination on Plasma Magnesium in Patients with Essential Hypertension Magnesium-Bulletin 4/84 Leary et. al. I Hydrochlorothiazide and amiloride combination on plasma magnesium 127 Effects of a hydrochlorothiazide and amiloride combination on plasma magnesium in patients with essential hypertension By W. P. Leary, A. J. Reyes and K. van derBy/ University of Natal, Durban, South Africa, and Universidad de la Republica and Fundaci6n Procardias, Montevideo, Uruguay Zusammenfassung treated group and six out of ten of the pa­ deployment of these substances Bei 21 ambulanten Patienten wurde tients in the HCTZ+AMl-treated group is not devoid of important side­ der EinfluB von 50 mg Hydrochlorothia­ exhibited plasma Mg concentrations be­ low 0. 75 mmoi.L - 1, after a mean duration effects [26, 27], amongst which zid allein (H) und in Kombination mit bodily Mg depletion is one of the 5 mg Amilorid (H +A) auf das Verhalten of treatment of 22 weeks. No significant des Plasma-Mg untersucht. Die Patienten differences existed between the effects most relevant [28]. Common wurden zufallig und unter Doppelblind­ the studied formulations had on plasma loop (e.g. furosemide) and distal M g. bedingungen den beiden Behandlungsar­ lt is concluded that the addition of tubular (e.g. hydrochlorothiazide, ten, die 23 Wochen tang durchgefiihrt chlorthalidone) diuretics have wurden, zugeordnet und erhielten taglich 5 mg amiloride to 50 mg hydrochlorothia­ zide does not help preventing the fall in been found to cause hypermag­ je eine Tablette. plasma Mg induced by 50 mg hydrochlo­ Beide Therapieformen waren am Ende nesiuresis in acute and chronic der Beobachtungszeit gleichermaBen an­ rothiazide upon prolonged administra­ studies carried out in normal tihypertensiv wirksam, obwohl die hypo­ tion. subjects and in patients suffering tensive Wirkung der Kombinationsbe­ from various conditions [28, handlung (H +A) schneller einsetzte. Resume Nach durchschnittlich 22 Wochen fiel 30, 34]. The ensuing bodily Mg L'effet de 50 mg d' hydrochlorothiazide depletion is the principal deter­ das Plasma-Mg in der (H)-Gruppe von (HCTZ) et celui d'une combinaison de 0,77 auf 0,70 mmol/1 (p < 0,05) und in der 50 mg d'hydrochlorothiazide et 5 mg minant of diuretic-induced car­ (H + A)-Gruppe von 0,82 auf d'amiloride (HCTZ+ AMI) sur le Mg diac arrhythmias (hitherto as­ 0,75 mmol/ 1 (p < 0,05). Sieben von neun plasmatique etaient etudies chez vingt­ cribed to K depletion) [24, Patienten der (H)-Gruppe und sechs von et-un malades ambulatoires avec hyper­ 28, 30], hampers the antihyper­ zehn der (H + A)-Gruppe hatten Plasma­ tension arterielle essentielle. Les malades Mg-Konzentrationen unter 0,75 mmol/ 1 etaient assignes, par hasard et douple­ tensive effect of diuretics [6], nach durchschnittlich 22 Behandlungs­ aveugle, au traitement avec HCTZ ou contributes to shifting the plasma wochen. Hinsichtlich des Plasma-Mg be­ HCTZ+AMT une fois par jour, pendant lipid profile towards a pattern of stehen zwischen der (H)- bzw. (H + A)­ 23 semaines. Gruppe keine signitikanten Unter­ high cardiovascular risk [28], and Les deux formulations montrerent des predisposes to sudden death and schiede. efticacies antihypertensives de la meme Es wird gefolgert, dal3 bei Langzeitbe­ magnitude finale, bien que l'effet de coronary and cerebrovascular handlung die zusatzliche Gabe von 5 mg l'HCTZ+AMI etait plus rapide que celui spasms [1, 7, 16, 18]. Amilorid nicht die durch 50 mg Hydro­ de l'HCTZ. La concentration plasmati­ chlorothiazid verursachte Abnahme des que du Mg tomba d'une moyenne de The K-sparing diuretic amilor­ Plasma-Mg verhindert. 0.77 mmol.L-1 avant le traitement a ide exhibits weak dose-depend­ 1 0.70 mmol.L- (p< O.OS) apn!s une ent, Mg-sparing actions when Summary moyenne de 22 semaines de therapie avec HCTZ. Pendant le meme periode, le ma­ single doses are administered to The effects on plasma Mg of 50 mg hy­ gnesium plasmatique descendu de 0.82 a healthy individuals [8, 17], wher­ drochlorothiazide (HCTZ) and those of a 0.74 mmoi.L- 1 (p <0.05) chez les malades 50 mg hydrochlorothiazide and 5 mg amil­ eas hydrochlorothiazide 50 mg traites avec HCTZ+AMT. Sept des neuf (HCTZ) causes significant hyper­ oride combination (HCTZ+ AMI) were malades traites avec HCTZ et six des dix studied in twenty-one ambulant patients des malades traites avec HCTZ + AMI magnesiuresis under similar ex­ suffering from essential hypertension. Pa­ eurent chiffres de Mg plasmatique infe­ perimental circumstances [ 15]. A tients were double-blind and randomly rieures au· limite normal de combination of 50 mg hydro­ allocated to treatment with one daily ta­ 0.75 mmol.L-1, apres une moyenne de blet of either formulation, for a 23-week chlorothiazide and 5 mg amilor­ 22 semaines de traitement. ide (HCTZ +AMI) has not been period. On conclut que !'addition de 5 mg Both formulations exerted equally effi­ d'amiloride ne previent pas la chute du found to induce a statistically cacious tinal antihypertensive effects, Mg plasmatique provoque par !'adminis­ significant increase in magnesi­ though the hypotensive action of tration journaliere de 50 mg d'hydrochlo­ uresis when a single dose is given HCTZ+ AMI proceeded at a higher rate rothiazide. than that of HCTZ. to normal subjects [10, 16]. In After an average of 22 weeks of ther­ consequence, it could be postu­ apy, plasma Mg fell from a pretreatment lated that HCTZ+AMI would Introduction mean value of 0.77 to 0.70 mmoi.L- 1 be less likely to induce a de­ (p < 0.05) in the HCTZ-treated group, and from 0.82 to 0.74 mmoi.L-1 (p<0.05) Diuretics are widely used in crease in bodily Mg than HCTZ, in the HCTZ+AMI-treated group. Seven the treatment of essential hyper­ when given chronically to hyper­ out of the nine patients in the HCTZ- tension. However, the chronic tensive patients. 128 Leary et al. I Hydrochlorothiazide and amiloride combination on plasma magnesium Magnesium-Bulletin 4/84 The objective of this study was diabetes mellitus requiring phar­ telet estimation and standard to comparatively assess the ef­ macological treatment; (xvi) urinalysis. Blood samples for fects of HCTZ+AMI and of rheumatic conditions requiring laboratory analyses were taken HCTZ on plasma Mg, during drug therapy; (xvii) respiratory 2-4 h after the last intake of medium-term administration to disorders requiring drug treat­ medication. patients with essential hyperten­ ment other than with antibiotics; sion. (xviii) anaemia or leucopenia; (xix) conditions requiring topical Operational procedures Patients and methods application of corticosteroids; (xx) any severe disease likely to At the first examination pa­ Patients interfere with the objectives of tients who were under antihyper­ Twenty-one males, clerical or the study, either per se or be­ tensive treatment had current manual workers, aged 35 to 56 cause of the necessary medica­ therapy withdrawn. Precise in­ years, were selected for the study tion; (xxi) psychotic disorders of structions were given that tablets after the objectives and implica­ any kind; (xxii) any specific con­ had to be taken at h 08.00 a.m. tions of the trial were explained traindication for any of the study and that magnesium-based anta­ to them, using the vernacular substances. cids could not be used during the where necessary to ensure that study. No medications other informed oral consent was ob­ Measurements than the trial formulations were tained. prescribed. One placebo tablet Twelve patients were Black Arterial pressures were mea­ was indicated to be ingested and nine were Caucasoid. All sured in the working arm by the daily for a 4-week baseline had morning resting supine dias­ standard indirect technique, period. After the end of the tolic blood pressures of using the first appearance and second week of this period, an­ 95-110 mm Hg (inclusive), re­ final disappearance of Korot­ other complete clinical evalua­ corded after 2 and 4 weeks of kofrs sounds to define systolic tion was performed, and an elec­ treatment with placebo. Patients and diastolic pressures respec­ trocardiogram, a chest X-ray and in whom comprehensive clinical tively. If sounds persisted to complete laboratory analyses - including ophthalmological 0 mm Hg, the point at which were carried out. -, laboratory electrical and ra- muffling occurred was taken as Patients with a supine diastolic diological investigations revealed the diastolic pressure reference. blood pressure of 95-110 mm one or more of the following, Patients rested · supine for Hg at the end of the second and were not included in the study: 10 minutes and erect for 3 min­ of the fourth week of the base­ (i) secondary hypertension of utes before measurement of the line period and who met none of any origin; (ii) malignant hyper­ corresponding blood pressures; the exclusion criteria proceeded tension; (iii) haemodynamically an average was obtained from to the active treatment phase of significant valvular heart dis­ three readings per patient in each the study. Patients were ran­ ease; (iv) congestive cardiac in­ bodily posture. The same mer­ domly and double-blind allo­ sufficiency; (v) left ventricular cury sphygmomanometer and cated to monotherapy with a insufficiency; (vi) right ventricu­ stethoscope were used through­ daily tablet of either HCTZ or lar insufficiency; (vii) sinus bra­ out the study and all clinical HCTZ +AMI. Arterial blood dycardia of less than 54.min- I evaluations and measurements pressure, pulse rate and body after 3 minutes supine rest; (viii) were made 2-4 h after the last weight were measured every 2 second or third degree atrio-ven­ intake of medication. weeks starting at the end of third tricular block; (ix) coronary in­ Serum Mg was measured by week of treatment. Plasma Mg, K sufficiency requiring pharmaco­ atomic absorption spectroscopy, and Na were measured every 2 logical treatment; (x) myocardial using a Yarian 275 instrument.
Load more

Recommended publications
  • Drugs and Life-Threatening Ventricular Arrhythmia Risk: Results from the DARE Study Cohort
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2017-016627 on 16 October 2017. Downloaded from Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort Abigail L Coughtrie,1,2 Elijah R Behr,3,4 Deborah Layton,1,2 Vanessa Marshall,1 A John Camm,3,4,5 Saad A W Shakir1,2 To cite: Coughtrie AL, Behr ER, ABSTRACT Strengths and limitations of this study Layton D, et al. Drugs and Objectives To establish a unique sample of proarrhythmia life-threatening ventricular cases, determine the characteristics of cases and estimate ► The Drug-induced Arrhythmia Risk Evaluation study arrhythmia risk: results from the the contribution of individual drugs to the incidence of DARE study cohort. BMJ Open has allowed the development of a cohort of cases of proarrhythmia within these cases. 2017;7:e016627. doi:10.1136/ proarrhythmia. Setting Suspected proarrhythmia cases were referred bmjopen-2017-016627 ► These cases have provided crucial safety by cardiologists across England between 2003 and 2011. information, as well as underlying clinical and ► Prepublication history for Information on demography, symptoms, prior medical and genetic data. this paper is available online. drug histories and data from hospital notes were collected. ► Only patients who did not die as a result of the To view these files please visit Participants Two expert cardiologists reviewed data the journal online (http:// dx. doi. proarrhythmia could be included. for 293 referred cases: 130 were included. Inclusion org/ 10. 1136/ bmjopen- 2017- ► Referral of cases by cardiologists alone may have criteria were new onset or exacerbation of pre-existing 016627).
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • DIURETICS Diuretics Are Drugs That Promote the Output of Urine Excreted by the Kidneys
    DIURETICS Diuretics are drugs that promote the output of urine excreted by the Kidneys. The primary action of most diuretics is the direct inhibition of Na+ transport at one or more of the four major anatomical sites along the nephron, where Na+ reabsorption takes place. The increased excretion of water and electrolytes by the kidneys is dependent on three different processes viz., glomerular filtration, tubular reabsorption (active and passive) and tubular secretion. Diuretics are very effective in the treatment of Cardiac oedema, specifically the one related with congestive heart failure. They are employed extensively in various types of disorders, for example, nephritic syndrome, diabetes insipidus, nutritional oedema, cirrhosis of the liver, hypertension, oedema of pregnancy and also to lower intraocular and cerebrospinal fluid pressure. Therapeutic Uses of Diuretics i) Congestive Heart Failure: The choice of the diuretic would depend on the severity of the disorder. In an emergency like acute pulmonary oedema, intravenous Furosemide or Sodium ethacrynate may be given. In less severe cases. Hydrochlorothiazide or Chlorthalidone may be used. Potassium-sparing diuretics like Spironolactone or Triamterene may be added to thiazide therapy. ii) Essential hypertension: The thiazides usually sever as primary antihypertensive agents. They may be used as sole agents in patients with mild hypertension or combined with other antihypertensives in more severe cases. iii) Hepatic cirrhosis: Potassium-sparing diuretics like Spironolactone may be employed. If Spironolactone alone fails, then a thiazide diuretic can be added cautiously. Furosemide or Ethacrymnic acid may have to be used if the oedema is regractory, together with spironolactone to lessen potassium loss. Serum potassium levels should be monitored periodically.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Heart Failure — Managing Newly Diagnosed and Decompensated
    Clinical Guideline Heart failure: Managing newly diagnosed and decompensated patients admitted to hospital 1. Confirmation of Diagnosis Person with signs and symptoms suggesting heart failure Detailed history and clinical examination Consider aetiology for new diagnosis of heart Suspected diagnosis Confirmed failure or underlying cause for exacerbation of of heart failure diagnosis of heart chronic heart failure and exclude treatable Diagnosis has not failure causes. been confirmed by Diagnosis confirmed Arrange other investigations: echocardiogram by previous . CXR echocardiogram . ECG . FBC . U&Es and Creatinine . LFTs . TFTs . RBG . Cholesterol If current echocardiogram not Diagnosis confirmed by clinically relevant, echocardiogram, if possible Heart failure excluded so request repeat performed as an in-patient review diagnosis echo, if possible and adhering to Advancing performed as an in- Quality heart failure (AQHF) patient indicators Heart failure with preserved ejection Heart failure due to significant left ventricular fraction / diastolic dysfunction (EF systolic dysfunction (EF < 40%) >55%) • Update primary diagnosis on PCIS / -Update primary diagnosis on PCIS Cerner and document in casenotes /Cerner and document in casenotes. Proceed to Management of Confirmed Heart Failure Heart failure — managing newly diagnosed and decompensated patients in acute care — clinical guidelines, v1 Principal author: Dr P Saravanan Approved by Medicines Clinical Guideline Team: July 2013 Review by: July 2016 Page 1 of 27 2. Inpatient management Heart failure with preserved Heart failure due to left ventricular ejection fraction systolic dysfunction (EF < 40%) • Referral to heart failure specialist team. • Arrange admission to appropriate ward/unit Refer to Heart Failure Fluid balance: Drug management: Specialist Nurse for 1. Fluid restriction 1-2 litres in 24 1.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Penetrating Topical Pharmaceutical Compositions Containing N-\2-Hydroxyethyl\Pyrrolidone
    Europaisches Patentamt ® J European Patent Office © Publication number: 0 129 285 Office europeen des brevets A2 (12) EUROPEAN PATENT APPLICATION © Application number: 84200823.7 ©Int CI.3: A 61 K 47/00 A 61 K 31/57, A 61 K 45/06 © Date of filing: 12.06.84 © Priority: 21.06.83 US 506273 © Applicant: THE PROCTER & GAMBLE COMPANY 301 East Sixth Street Cincinnati Ohio 45201 (US) © Date of publication of application: 27.12.84 Bulletin 84/52 © Inventor: Cooper, Eugene Rex 2425 Ambassador Drive © Designated Contracting States: Cincinnati Ohio 4523KUS) BE CH DE FR GB IT LI NL SE © Representative: Suslic, Lydia et al, Procter & Gamble European Technical Center Temseiaan 100 B-1820 Strombeek-Bever(BE) © Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl)pyrrolidone. Topical pharmaceutical compositions comprising a pharmaceutically-active agent and a novel, penetration- enhancing vehicle or carrier are disclosed. The vehicle or carrier comprises a binary combination of N-(2-Hydroxyethyl) pyrrolidone and a "cell-envelope disordering compound". The compositions provide marked transepidermal and per- cutaneous delivery of the active selected. A method of treat- ing certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed. TECHNICAL FIELD i The present invention relates to compositions which enhance the utility of certain pharmaceutically-active agents by effectively delivering these agents through the integument. Because of the ease of access, dynamics of application, large surface area, vast exposure to the circulatory and lymphatic networks, and non-invasive nature of the treatment, the delivery of pharmaceutically-active agents through the skin has long been a promising concept.
    [Show full text]
  • Ш„ ^Гг Тііи CLINICAL PHARMACOLOGICAL STUDIES on TIENILIC ACID and FUROSEMIDE Promotores: Prof
    D D π Ш π α π • Q ÛDD fDSDUO Q ^г^ ш„ ^гг тііи CLINICAL PHARMACOLOGICAL STUDIES ON TIENILIC ACID AND FUROSEMIDE Promotores: Prof. dr F. W. J. GRIBNAU Prof. dr С. Α. Μ. van GINNEKEN CLINICAL PHARMACOLOGICAL STUDIES ON TIENILIC ACID AND FUROSEMIDE PROEFSCHRIFT ter verkrijging van de graad van doctor in de Geneeskunde aan de Katholieke Universiteit te Nijmegen, op gezag van de rector magnificus Prof. dr J. H. G. I. Giesbers, volgens het besluit van het college van dekanen in het openbaar te verdedigen op donderdag 24 maart 1983 des namiddags te 2 uur precies door ADRIANUS LAMBERTUS MARIA KERREMANS geboren te Roosendaal И krips repro meppel The studies presented in this thesis were performed in - the Department of Internal Medicine - the Institute of Pharmacology of the University of Nijmegen, The Netherlands; and in - the Nursing home 'Irene" H. Landstichting - the Canisius-Wilhelmina Hospital Nijmegen Aan Mariette Jos, Sanne en Mechteld Aan mijn ouders CONTENTS Chapter I GENERAL INTRODUCTION AND PROBLEM STATEMENT page Chapter II DIURETICS 2.1 renal transport of sodium and chloride 2.2 renal transport of uric acid 2.3 site of action and mode of action of diuretics 2.4 tienilic acid 2.5 furosemide references Chapter III SOME FACTORS INFLUENCING DRUG RESPONSE 2 3.1 influence of age on pharmacokinetics and pharmacodynamics 3.2 influence of long-term treatment 3.3 congestive heart failure and its influence on sodium homoeostasis and on disposition and effect of diuretics 3.4 diuretic resistance in congestive heart failure references Chapter IV METHODS 4 4.1 HPLC 4.2 protein binding of drugs 4.3 pharmacokinetics 4.4 dose-response curves references Chapter V PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF TIE- 6 NILIC ACID IN HEALTHY VOLUNTEERS Eur J Clin Pharmacol 1982, 22, 515-521.
    [Show full text]
  • Azosemide Is More Potent Than Bumetanide and Various Other Loop
    www.nature.com/scientificreports OPEN Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium- Received: 21 November 2017 Accepted: 14 June 2018 potassium-chloride-cotransporter Published: xx xx xxxx human variants hNKCC1A and hNKCC1B Philip Hampel 1,2, Kerstin Römermann1, Nanna MacAulay 3 & Wolfgang Löscher1,2 The Na+–K+–2Cl− cotransporter NKCC1 plays a role in neuronal Cl− homeostasis secretion and represents a target for brain pathologies with altered NKCC1 function. Two main variants of NKCC1 have been identifed: a full-length NKCC1 transcript (NKCC1A) and a shorter splice variant (NKCC1B) that is particularly enriched in the brain. The loop diuretic bumetanide is often used to inhibit NKCC1 in brain disorders, but only poorly crosses the blood-brain barrier. We determined the sensitivity of the two human NKCC1 splice variants to bumetanide and various other chemically diverse loop diuretics, using the Xenopus oocyte heterologous expression system. Azosemide was the most potent NKCC1 inhibitor (IC50s 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B), being about 4-times more potent than bumetanide. Structurally, a carboxylic group as in bumetanide was not a prerequisite for potent NKCC1 inhibition, whereas loop diuretics without a sulfonamide group were less potent. None of the drugs tested were selective for hNKCC1B vs. hNKCC1A, indicating that loop diuretics are not a useful starting point to design NKCC1B-specifc compounds. Azosemide was found to exert an unexpectedly potent inhibitory efect and as a non-acidic compound, it is more likely to cross the blood-brain barrier than bumetanide. Te Na+–K+–2Cl− cotransporter NKCC1 (encoded by SLC12A2) plays an important role in Cl- uptake in neu- rons both in developing brain and in adult sensory neurons1,2.
    [Show full text]
  • Diuretics Drug Information
    Diuretics The information in this leaflet is intended for general guidance. If your doctor has given you different advice, follow their instructions. Your GP may give you the same tablets known by a different name — the brand name. You should always check with your GP or pharmacist if you are unsure. Examples Furosemide, Amiloride, Bendroflumethiazide, Bumetanide, Metalozone and Spironolactone. The above drugs might also be referred to by the trade name assigned by the manufacturer. What are diuretics used for? Diuretics are primarily used for people with heart failure and possibly for treatment of high blood pressure. How do they work? When your heart is not pumping effectively this will effect how much urine the kidneys produce. With a decrease in urine production your body will carry an excess of fluid potentially causing your breathing to become more rapid and uncomfortable. Diuretics work directly on your kidneys to produce more urine and remove the excess fluid from your body. This will help your breathing become easier and also help reduce swelling of the ankles and legs. It will also reduce your blood pressure. Source: Cardiology Reference no: 5349-2 Issue date: 25/4/19 Review date: 25/4/22 Page 1 of 2 Possible side effects Dizziness and feeling faint Lethargy Rash If you are concerned please contact your doctor. The side effects will vary on the type of diuretic you are taking. What if I miss a dose? Try to take your diuretic tablet the same time each day preferably in the morning. If you forget you can take it later in the day up to 2pm.
    [Show full text]
  • For Peer Review Only
    BMJ Open BMJ Open: first published as 10.1136/bmjopen-2013-003424 on 24 September 2013. Downloaded from BMJ Open: first published as 10.1136/bmjopen-2013-003424 on 24 September 2013. Downloaded from Rosiglitazone use and post-discontinuation glycaemic control in two European countries, 2000-2010 ForJournal: peerBMJ Open review only Manuscript ID: bmjopen-2013-003424 Article Type: Research Date Submitted by the Author: 17-Jun-2013 Complete List of Authors: Ehrenstein, Vera; Aarhus University Hospital, Department of Clinical Epidemiology Hernandez, Rohini; Amgen, Inc., Center for Observational Research Ulrichsen, Sinna; Aarhus University Hospital, Department of Clinical Epidemiology Rungby, Jørgen; Aarhus University Hospital, Department of Biomedicine - Pharmacology Lash, Timothy; Emory University Rollins School of Public Health, Department of Epidemiology Riis, Anders; Aarhus University Hospital, Department of Clinical Epidemiology Li, Lin; Boston University School of Medicine, Boston Collaborative Drug Surveillance Program Toft Sørensen, Henrik; Aarhus University Hospital, Department of Clinical Epidemiology http://bmjopen.bmj.com/ Jick, Sn; Boston University, ; Boston University School of Medicine, Boston http://bmjopen.bmj.com/ Collaborative Drug Surveillance Program <b>Primary Subject Epidemiology Heading</b>: Secondary Subject Heading: Pharmacology and therapeutics, Public health diabetes mellitus, drug safety, glucose-lowering drugs, rosiglitazone, Keywords: on September 27, 2021 by guest. Protected copyright. thiazolidinediones on September 27, 2021 by guest. Protected copyright. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 50 BMJ Open BMJ Open: first published as 10.1136/bmjopen-2013-003424 on 24 September 2013. Downloaded from 1 2 Rosiglitazone use and post-discontinuation glycaemic control in two European countries, 3 4 2000-2010 5 6 7 8 9 10 1* 2,3** 1 4 1,5 1 11 V.
    [Show full text]
  • Should We Switch from Bendrofluazide to Chlorthalidone As the Initial Treatment for Hypertension? a Review of the Available Medication
    ORIGINAL SCIENTIFIC PAPER SYSTEMatic REVIEW Should we switch from bendrofluazide to chlorthalidone as the initial treatment for hypertension? A review of the available medication Bruce Arroll MBChB, PhD, FRNZCGP; Henry Wallace Department of General Practice and Primary ABSTRACT Health Care, University of Auckland, Private Bag INTRODUCTION: Thiazide diuretics are commonly prescribed in the treatment of hypertension. 92019, Auckland 1142, However, thiazide diuretics may not all be equal in their ability to reduce cardiovascular New Zealand disease outcomes. AIM: To determine if bendroflumethiazide/bendrofluazide, the most commonly used diuretic for hypertension in New Zealand, is as effective as other diuretics in terms of cardiovascular disease outcomes. METHODS: Using recent reviews of thiazide-like (chlorthalidone or indapamide) and thiazide-type diuretics (hydrochlorothiazide and bendrofluazide) and a separate search of bendrofluazide, data on cardiovascular disease outcomes was extracted. RESULTS: Nineteen relevant papers with 21 comparisons were found. All thiazide-based diu- retics have been reported in at least one trial showing them to be more effective than placebo for cardiovascular disease outcomes, with the exception of chlorothiazide. There were no comparisons of bendrofluazide alone with other medications, but there were two studies with either bendrofluazide or hydrochlorothiazide compared withb -blockers; however, the pooled relative risk (RR) was not significant (RR = 1.10 (95% CI, 0.84–1.43)). For chlorthalidone, there were four comparisons with other medications, and the summary RR was statistically signifi- cant for cardiovascular disease outcomes (RR = 0.91 (95% CI, 0.85–0.98)). Chlorthalidone was significantly more effective for some cardiovascular disease outcomes when compared with doxazosin, amlodipine and lisinopril.
    [Show full text]